The use of corticosteroids in the treatment of the acute or Post-Covid phase should be used only when necessary. By their action, they stop pro-inflammatory molecules that further damage organs. There is a fine line between healing and disrupting the natural course of disease and healing. Unnecessary use of corticosteroids can also lead to unnecessary side effects. The use of these drugs in different stages of illness and recovery from COVID-19 was intended to reduce lung damage and speed up the healing process. We observed the participants in this study in two separate divisions. The first division was based on the use of corticosteroids in patients in the acute phase of COVID-19, acute and post-Covid phase, post-Covid phase, and those who did not receive corticosteroid therapy in general. The second division was based on whether they were hospitalized – not in an intensive care unit, hospitalized in an intensive care unit, or treated outside the hospital. The aim of this study was to demonstrate the association between the use of corticosteroid therapy and where they have been through the acute phase of COVID-19 with treatment outcomes suggestive of interstitial lung disease. Based on this research, it was observed that the best treatment outcomes are when corticosteroid therapy is not used at all, and if they are already applied then the best results are in the post-Covid period. Furthermore, people treated in outpatient settings have a faster recovery, which could have been expected because their health was good enough during acute COVID-19 disease that they do not have to be hospitalized.